References
1. Kellum J., et al. Endotoxemic sepsis: clinical features and therapy. J Transl Crit Care Med. 2022; 4 (1): 13.
2. Putzu A., et al. Blood purification and mortality in sepsis and septic shock. Anesthesiology. 2019; 131 (3): 580–93.
3. Marshall J.C., et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004; 190 (3): 527–34.
4. Fujimori K., Tarasawa K., Fushimi K. Effects of polymyxin b hemoperfusion on septic shock patients requiring noradrenaline: analysis of a nationwide administrative database in Japan. Blood Purif. 2021; 50 (4–5): 560–5.
5. Fujimori K., Tarasawa K., Fushimi K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Ann Intensive Care. 2021; 11 (1): 141.
6. Ricci Z., et al. Hemoperfusion in the intensive care unit. Intensive Care Med. 2022; 48 (10): 1397–408.
7. Stanski N.L., Wong H.R. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol. 2020; 16 (1): 20–31.
8. Rimmel T., Kellum J.A. Clinical review: blood purification for sepsis. Crit Care. 2011; 15 (1): 205.
9. Wiersinga W.J., et al. Host innate immune responses to sepsis. Virulence. 2914; 5 (1): 36–44.
10. Dargent A., et al. Improved quantification of plasma lipopolysaccharide (LPS) burden in sepsis using 3-hydroxy myristate (3HM): a cohort study. Intensive Care Med. 2019; 45 (11): 1678–80.
11. Schultz P., et al. High-dose CytoSorb hemoadsorption is associated with improved survival in patients with septic shock: a retrospective cohort study. J Crit Care. 2021; 64: 184–92.
12. Dellinger R.P., et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018; 320 (14): 1455–63.
13. Aoki H., Tani T. Treatment of sepsis by extracorporeal elimination of endotoxin using polyrnyxin B-immobilized fiber. Am J Surg. 1994; 167 (4): 412–7.
14. Nozaka Kimiyasu, et al. Case report of septic shock after operation improved by 4th polymyxin-B immobilized fiber therapy (PMX-DHP). Jpn J Crit Care Endotoxemia. 2003; 7: 190–3.
15. Novelli G., et al. Clinical results of treatment of postsurgical endotoxin-mediated sepsis with polymyxin-B direct hemoperfusion. Transplant Proc. 2010; 42 (4): 1021–4.
16. Rybalko A., et al. Case report: successful use of extracorporeal therapies after ECMO resuscitation in a pediatric kidney transplant recipient. Front Pediatr. 2020; 8: 593123.
17. Takeda S., et al. Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intensive Care Med. 2010; 36 (5): 906–7.
18. Novelli G., et al. Polymixin-B hemoperfusion in a case intolerant to conventional antibiotic therapy. J Biomed Sci Eng. 2012; 5 (3): 101–3.
19. Wei Q., et al. Successful treatment of crush syndrome complicated with multiple organ dysfunction syndrome using hybrid continuous renal replacement therapy. Blood Purif. 2009; 28 (3): 175–80.
20. Evans L., et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021; 47 (11): 1181–247.